comparemela.com

Latest Breaking News On - Hart scott rodino antitrust improvements - Page 20 : comparemela.com

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development,

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development,
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

AstraZeneca Receives U S FTC Clearance For Proposed Acquisition Of Alexion Pharma

AstraZeneca Receives U.S. FTC Clearance For Proposed Acquisition Of Alexion Pharma LONDON (dpa-AFX) - British drug major AstraZeneca Plc. (AZN.L, AZN) said Friday that it has received a clearance from the U.S. Federal Trade Commission for its proposed acquisition of Alexion Pharmaceuticals Inc (ALXN). It follows the conclusion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The clearance follows competition clearances in Canada, Brazil, Russia and other countries globally. Additional global regulatory clearances are pending, including but not limited to the UK, EU and Japan. The acquisition remains expected to close in the third-quarter 2021, subject to receipt of additional global regulatory clearances and approval by shareholders of both companies with shareholder voting anticipated on 11 May 2021.

AstraZeneca receives US clearance for proposed acquisition of Alexion | 16 April 2021

16 April 2021 | 15:00pm StockMarketWire.com - AstraZeneca s proposed acquisition of Alexion Pharmaceuticals has been cleared by the US Federal Commission, following the end of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The announcement follows competition clearances in Canada, Brazil, Russia and other countries globally. Additional global regulatory clearances are pending, including but not limited to the UK, EU and Japan. Marc Dunoyer, executive director and chief financial officer (CFO), said: These clearances further advance us towards closing our acquisition of Alexion. We remain focused on the next chapter for AstraZeneca and Alexion, building on our combined expertise in immunology and precision medicines and our shared ambition to bring more innovative medicines to patients worldwide. We look forward to working closely with other global authorities as we progress toward this goal.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.